AZ SB1052

Requires disability insurers and group/blanket disability insurers issuing or renewing policies on or after January 1, 2023 to provide coverage for biomarker testing.

Covers biomarker testing for diagnosis, treatment, management, or monitoring of diseases or conditions when the test demonstrates clinical utility as evidenced by FDA approval, CMS coverage determinations, or nationally recognized clinical practice guidelines and consensus statements.

Requires insurers to limit disruptions in care by minimizing the need for multiple biopsies or biospecimen samples.

Mandates that insurers provide a clear, accessible, and convenient process on their websites for insureds and prescribing practitioners to request exceptions to coverage policies.

Defines key terms including "biomarker" (objectively measured indicator including gene mutations or protein expression), "biomarker testing" (analysis of tissue, blood, or biospecimens), and "clinical utility" (test results used to formulate treatment or monitoring strategies that inform patient outcomes).